Skip to content

GenSight Biologics Reports Full Year 2016 Financial Results

Paris, France, March 13, 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced its full year 2016 financial results.

Please find the full PDF press release attached.

Contacts

GenSight Biologics
Thomas Gidoin
Chief Financial Officer
ir@gensight-biologics.com
+33 (0)1 76 21 72 20
NewCap
I
nvestor Relations
Florent Alba
gensight@newcap.eu
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

Source: GenSight Biologics